iOnctura's roginolisob has potential for patients with solid and hematological tumors 21-Mar-2023 By Liza Laws Non-clinical research has been published about roginolisob, iOnctura’s non-ATP competitive alloseteric modulator of PI3Kδ, for the potential treatment of patients with solid and hematological tumors.